Vegzelma is indicated for treating metastatic breast cancer, advanced and/or metastatic renal cell cancer and non-small cell lung cancer, among others. Credit: Atlas of Pulmonary Pathology / Flickr (Creative Commons).

The European Commission (EC) has granted approval for Celltrion Healthcare’s Vegzelma (CT-P16) to treat metastatic breast cancer, advanced and/or metastatic renal cell cancer, non-small cell lung cancer, ovarian cancer, metastatic carcinoma of the colon or rectum and cervical cancer.

Vegzelma (CT-P16) is a bevacizumab biosimilar referencing Genentech’s Avastin, which is approved in the EU.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The latest development comes after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorisation for Vegzelma in June.

Based on the totality of findings, including those from the Phase III clinical trial of Vegzelma in metastatic or recurrent non-squamous non-small cell lung cancer patients, the EC granted approval. 

According to the findings, Vegzelma as first-line therapy was found to be similar in terms of safety, efficacy and pharmacokinetics to the reference product. 

See Also:

An anti-cancer treatment biosimilar to Avastin, Vegzelma is a recombinant humanised monoclonal antibody which attaches to VEGF.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It thus hinders VEGF binding to its receptors Flt-1 (VEGFR-1) and kinase insert domain receptor (KDR) (VEGFR-2) on the endothelial cell surface. 

Vegzelma is said to be the third oncology biosimilar of Celltrion to receive approval in the EU.

In September last year, the company sought regulatory approval from the US Food and Drug Administration (FDA) for Vegzelma.

The approval is anticipated in the third quarter of this year.

Celltrion Healthcare senior vice-president and marketing division head Kevin Byoung Seo Choi said: “The European Commission’s approval of Vegzelma will increase access to treatment for patients living with certain types of cancer at an affordable price. 

“With proven similarities in efficacy and safety compared to the reference product Avastin, Vegzelma will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.”